FOPO nets $40.5mm for Five Prime
Executive Summary
Five Prime Therapeutics Inc. (therapies for cancer and inflammatory diseases) netted $40.5mm through the follow-on public offering of 3.45mm common shares (including the overallotment) at $12.50 each. Some of the funds will support ongoing clinical trials of its CSF1R antibody FPA008 for autoimmune disease, and to move preclinical FPA144, an FGFR2b antibody for gastric cancer, into the clinic.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice